Dynavax to Present at Upcoming Investment Conferences

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in several upcoming investor conferences, showcasing its commitment to vaccine development. Key presentations include the 2021 Cantor Virtual Global Healthcare Conference on September 30 at 12:00 p.m. E.T., the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5 at 12:00 p.m. E.T., and the H.C. Wainwright 2nd Hepatitis B Virus Virtual Conference on October 13 at 12:00 p.m. E.T.. All events will be available via live webcast on their website's 'Events & Presentations' page.

EMERYVILLE, Calif., Sept. 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that it will participate in the following investor conferences.

2021 Cantor Virtual Global Healthcare Conference
Dynavax Presentation: Thursday, September 30, 2021, 12:00 p.m. E.T.

Guggenheim 2nd Annual Vaccine and Infectious Disease Conference
Fireside Chat: Tuesday, October 5, 2021, 12:00 p.m. E.T.

H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual Conference
Fireside Chat: Wednesday, October 13, 2021, 12:00 p.m. E.T.

All the conferences are being held virtually. A live webcast of each of the presentations will be available and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as an advanced vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-upcoming-investment-conferences-301385981.html

SOURCE Dynavax Technologies

FAQ

What conferences is Dynavax Technologies presenting at in September 2021?

Dynavax is presenting at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021.

When is the Guggenheim Vaccine and Infectious Disease Conference?

The Guggenheim 2nd Annual Vaccine and Infectious Disease Conference is on October 5, 2021, at 12:00 p.m. E.T.

What is the date of the H.C. Wainwright Hepatitis B Virus Virtual Conference?

The H.C. Wainwright 2nd Hepatitis B Virus Virtual Conference is scheduled for October 13, 2021, at 12:00 p.m. E.T.

Where can I watch the Dynavax conference presentations?

The presentations can be accessed via live webcast on the 'Events & Presentations' page of Dynavax's website.

What is the main focus of Dynavax Technologies?

Dynavax focuses on developing and commercializing vaccines, with its first product being HEPLISAV-B for hepatitis B.